Hikma Pharmaceuticals PLC
Volume 164 · 164 F.T.C. 1121
Cite this decision
Hikma Pharmaceuticals PLC, 164 F.T.C. 1121 (2017). Consumer Law Library, https://consumerlawlibrary.org/decisions/v164-0037
Report an error in this record (decision id v164-0037)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MATTER OF HIKMA PHARMACEUTICALS PLC Docket No. C-4568. Order, December 6, 2017 Letter notifying Hikma Pharmaceuticals plc of the Commission’s decision to waive prior approval and public comment regarding modifications to the Supply Agreement and Asset Purchase Agreement. LETTER WAIVING PRIOR APPROVAL AND COMMENT FOR MODIFICATIONS TO AGREEMENTS Maria Raptis, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP Re: In the Matter of Hikma Pharmaceuticals plc, Docket No. C-4568 Dear Ms. Raptis:
This letter refers to an application for approval that Hikma Pharmaceuticals plc (“Hikma”) filed on October 23, 2017, which requested Commission approval of a proposed amendment to the Supply Agreement (Prednisone) and Asset Purchase Agreement, incorporated by reference into the Decision and Order entered into in this case.1 After consideration of Hikma’ s application n and pursuant to the authority delegated to me under Rule 2.41(f)(5)(ii) of the Commission’s Rules of Practice, 16 C.F.R. § 2.41(f)(5)(ii), I hereby waive the requirements for Commission approval and the public comment period for the amendment to the Supply Agreement and Asset Purchase Agreement described in Hikma’s application.
If you have further questions, please contact David von Nirschl, the Compliance staff attorney assigned to this matter. 1 Order ¶¶ I.RR., II.A., and VI.
VOLUME 164 Interlocutory Orders, Etc.
David von Nirschl can be reached at 202-326-3213 or [email protected].
FRESENIUS MEDICAL CARE AG & CO. KGAA 1123 Interlocutory Orders, Etc.